Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)

Sponsor
Merck KGaA, Darmstadt, Germany (Industry)
Overall Status
Completed
CT.gov ID
NCT01080053
Collaborator
Merck Quimica Argentina S.A.I.C (Industry)
306
1
53.9
5.7

Study Details

Study Description

Brief Summary

This is an observational, prospective, non-interventional, non-controlled study planned to be conducted in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).

The purpose of this observational study is to determine the correlation between the degree of disability and sexual dysfunction; and between the sexual dysfunction and the quality of life (QoL) of subjects with Relapsing Remitting Multiple Sclerosis (RRMS) in Argentina.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Multiple sclerosis, like most of the chronic diseases, can affect the sexuality of those who suffer from it. This situation has an evident and marked impact on the QoL of the subjects and his/her partner, and causes conflict in the relationship, with high levels of mutual dissatisfaction.

    The impact that the duration of the disease or the degree of disability have on the level of sexual dysfunction is not clear. However, the possible organic and state of mind causes of the sexual dysfunction makes us think that the degree of disability is a crucial factor in the genesis and duration of the symptoms in the sexual area. The frequency with which the sexual dysfunction is detected or referred in these subjects is variable.

    The sexual dysfunction in subjects with MS is typically characterized by a decreased libido, erectile dysfunction and ejaculation disorders in men, and decreased lubrication and anorgasmia in women. The most commonly detected problems are the erectile dysfunction and/or lack of sexual interest in men and lack of interest, decreased libido and orgasmic disorder in women.

    This observational study aims to assess a population of subjects with MS that show symptoms of sexual dysfunction, in order to determine the relationship, if any, between the severity of the general disability and the incidence of sexual dysfunction. At the same time, this epidemiologic study aims to measure the impact the sexual dysfunction generates in the quality of life of subjects with MS.

    The data to be obtained could contribute to a better understanding of the relationship between the studied variables and, eventually, to alert the treating doctors about the incidence of these morbid associations.

    The total duration of the study is 24 months. The recruiting period will be 12 months. Once the recruiting time is over, the collection of data will continue during the full 24 months period that was planned.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    306 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Observational Study to Determine the Relationship Between the Degree of Disability and the Presence of Sexual Dysfunction and Between Sexual Dysfunction and the Quality of Life in Patients With Multiple Sclerosis (RRMS)
    Study Start Date :
    Nov 1, 2008
    Actual Primary Completion Date :
    May 1, 2013
    Actual Study Completion Date :
    May 1, 2013

    Outcome Measures

    Primary Outcome Measures

    1. The correlation between the degree of disability and sexual dysfunction, and between the sexual dysfunction and the QoL of subjects [Initial visit (Day 0) and each follow up visit upto the observation period of 24 months]

      Mini-Mental State Examination (MMSE) Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) Hamilton Rating Scale for Depression (HRSD)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    22 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Men and women > 21 years of age

    • Subjects with established diagnosis of RRMS according to the revised McDonald criteria

    • 2005

    • Subjects with a diagnosis of RRMS for more than one year

    • The subject who have signed the Informed Consent

    Exclusion Criteria:
    • Subjects with no sexual experience

    • Subjects with other diseases associated to MS

    • Subjects with psychiatric diseases that could cause sexual dysfunction

    • Subjects with one relapse during the previous month

    • Use of antidepressants and/or corticosteroids during the previous month

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dr. Norma Deri Buenos Aires Argentina

    Sponsors and Collaborators

    • Merck KGaA, Darmstadt, Germany
    • Merck Quimica Argentina S.A.I.C

    Investigators

    • Principal Investigator: Norma Deri, PhD,

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Merck KGaA, Darmstadt, Germany
    ClinicalTrials.gov Identifier:
    NCT01080053
    Other Study ID Numbers:
    • EMR200077-511
    First Posted:
    Mar 3, 2010
    Last Update Posted:
    Oct 16, 2013
    Last Verified:
    Oct 1, 2013
    Keywords provided by Merck KGaA, Darmstadt, Germany
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 16, 2013